{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stetten NE"],"funding":["NIA NIH HHS"],"pagination":["1598-1601"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12424504"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["115(10)"],"pubmed_abstract":["Transgender people's access to gender-affirming hormone therapy (GAHT) is under attack in the United States. In 2024, we interviewed US providers about how they prescribe GAHT. In accordance with informed consent models, providers reported that they reviewed patients' medical history, social supports, and comorbidities; prescribed GAHT formulations that aligned with patients' goals; monitored health regularly; and maintained open communication with patients. The GAHT prescribers followed clinical standards to mitigate risks and maximize benefits, following similar standards of care for cisgender patients. (<i>Am J Public Health</i>. 2025;115(10):1598-1601. https://doi.org/10.2105/AJPH.2025.308143)."],"journal":["American journal of public health"],"pubmed_title":["Understanding Provider Treatment Approaches for the Provision of Gender-Affirming Hormones in the Current US Political Climate."],"pmcid":["PMC12424504"],"funding_grant_id":["R01 AG073440"],"pubmed_authors":["Shireman TI","Wolfe HL","Hughto JMW","Alpert AB","Meyers DJ","Stetten NE","Balkan E","Kelly PJA","Babbs G"],"additional_accession":[]},"is_claimable":false,"name":"Understanding Provider Treatment Approaches for the Provision of Gender-Affirming Hormones in the Current US Political Climate.","description":"Transgender people's access to gender-affirming hormone therapy (GAHT) is under attack in the United States. In 2024, we interviewed US providers about how they prescribe GAHT. In accordance with informed consent models, providers reported that they reviewed patients' medical history, social supports, and comorbidities; prescribed GAHT formulations that aligned with patients' goals; monitored health regularly; and maintained open communication with patients. The GAHT prescribers followed clinical standards to mitigate risks and maximize benefits, following similar standards of care for cisgender patients. (<i>Am J Public Health</i>. 2025;115(10):1598-1601. https://doi.org/10.2105/AJPH.2025.308143).","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-06T21:39:47.471Z","creation":"2026-06-05T03:11:53.842Z"},"accession":"S-EPMC12424504","cross_references":{"pubmed":["40811777"],"doi":["10.2105/AJPH.2025.308143","10.2105/ajph.2025.308143"]}}